Target @$8.00 date Jan 10,2022 Buy limit 500 ITRM @$1.40. Guru’s Opinion on Iterum Therapeutics plc [ITRM]: Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ITRM shares is $1.50 per share. Iterum Therapeutics Plc Stock Forecast NASDAQ:ITRM Price Target and Analyst Ratings. This is a -7.19 percent down since the beginning of the trading day. Iterum Therapeutics plc is followed by the analysts listed above. Furthermore, Iterum Therapeutics plc (ITRM)’s beta value is 0, and its average true range (ATR) is 0.33. Press Release reported on 03/16/21 that Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors. Iterum Therapeutics (ITRM) Receives a Hold from H.C. Wainwright. Iterum Therapeutics is selling for 1.41 as of the 27th of March 2021. SVB Leerink analyst A. Fadia now forecasts that the company will earn ($2.36) per share for the year, down from their prior forecast of ($2.34). The report will be for the fiscal Quarter ending Dec 2020. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in … Iterum Therapeutics plc (NASDAQ:ITRM) has a beta value of 0 and has seen 7,748,217 shares traded in the last trading session. Capital Management Lp Ra is the largest individual Iterum Therapeutics shareholder, owning 11.65M shares representing 27.07% of the company. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The one-year ITRM stock forecast points to a potential downside of -18.0. Iterum Therapeutics plc (NASDAQ:ITRM) went down by -0.70% from its latest closing price compared to the recent 1-year high of $6.02. Iterum Therapeutics is United States Stock traded on NASDAQ Exchange These shares represent 10.6 percent of ownership in the … But as Iterum Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions. The stock's lowest day price was 1.32. Since then, ITRM stock has decreased by 30.5% and is now trading at $1.41. All times are ET. Following the transaction, the insider now directly holds 1.23 million shares of the ITRM stock. Show section. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Iterum Therapeutics has generated ($7.10) earnings per share over the last year. Predicted Opening Price for Iterum Therapeutics Plc of Wednesday, March 24, 2021. Iterum Therapeutics Plc (ITRM) Stock Price Prediction By Analysts. Get the latest Iterum Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Iterum investment advice, charts, stats and more. But as Iterum Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions. The high price target for ITRM is $7.00 and the low price target for ITRM is $1.50. See Iterum Therapeutics plc (ITRM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Iterum Therapeutics plc is followed by the analysts listed above. What is ITRM's forecast return on assets (ROA) for 2021-2024? Guru’s Opinion on Iterum Therapeutics plc [ITRM]: At that level they are trading at 31.19% premium to the analyst consensus target price of 0.00. Iterum Therapeutics PLC (NASDAQ:ITRM) – Research analysts at SVB Leerink reduced their FY2020 earnings per share estimates for shares of Iterum Therapeutics in a report issued on Tuesday, October 20th. ITRM 1.41 0.01 (0.70%). What is ITRM's earnings growth forecast for 2021-2023? About the Iterum Therapeutics Plc stock forecast. The stock's lowest day price was 1.32. Iterum Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 13th, 2021 based off prior year's report dates. Iterum stock price target cut to … ... Iterum Therapeutics (ITRM) stock is taking off on Tuesday with heavy trading even without any news coming from the company. What this means: InvestorsObserver gives Iterum Therapeutics Plc (ITRM) an overall rank of 32, which is below average. So we'd only buy after very careful consideration. Click here now. CNN Sans™ & © 2016 Cable News Network. On average, Wall Street analysts predict that. Capital Management Lp Ra is the largest individual Iterum Therapeutics shareholder, owning 11.65M shares representing 27.07% of the company. Volume today is more active than usual. Trending now. View which stocks have … Taking a look at stock … Is Iterum Therapeutics Stock a good buy in 2021, according to Wall Street analysts? Get the latest Iterum Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Iterum investment advice, charts, stats and more. Iterum Therapeutics plc (NASDAQ:ITRM) concluded the trading at $1.41 on Friday, Mar 26, with a fall of -0.61% from its closing price on previous day. ET on SmarterAnalyst. The predicted opening price is based on yesterday's movements between high, low, and the closing price. Iterum Therapeutics plc disclosed in a document filed with the SEC on Jun 02 that Sofinnova Venture Partners IX, (10% Owner) sold a total of 400,000 shares of the company’s common stock. Iterum Therapeutics is selling for 1.42 as of the 25th of March 2021. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. This is a -0.7 percent decrease since the beginning of the trading day. Over the last … The stock has a consensus analyst rating of "Buy." Iterum Therapeutics plc Ordinary Share (ITRM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Last 30 Days. View Iterum Therapeutics PLC ITRM investment & stock information. Find the latest Earnings Report Date for Iterum Therapeutics plc Ordinary Share (ITRM) at Nasdaq.com. Shares in Iterum Therapeutics are currently priced at $2.07. The average price target is $2.25 with a high forecast of $2.50 and a low forecast of $2.00.The average price target represents a 40.63% increase from the last price of $1.60. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Toggle navigation. A Warner Media Company. ET by Tomi Kilgore. The stock has traded between $1.63 and $2.44 so far today. The stock touched a low price of $1.32. ... Analyst Forecasts. The average equity rating for ITRM stock is currently 3.20, trading closer to a bullish pattern in the stock market. HC Wainwright is very positive to ITRM and gave it a "Neutral - Buy" rating on March 22, 2021. This price target is based on 4 analysts offering 12 month price targets for Iterum Therapeutics in the last 3 months. Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. This is a -0.7 percent decrease since the beginning of the trading day. Based on 2 analysts offering 12 month price targets for Iterum Therapeutics in the last 3 months. A Upward trend indicates that Iterum Therapeutics Plc (ITRM) Stock Price may keep going up, with temporary Retracement (the process of stock price bouncing because of short term profit taking by the traders and investors). - Try Now Risk-Free - Money-back guarantee! Most stock quote data provided by BATS. View the real-time ITRM price chart on Robinhood and decide if you want to buy or sell commission-free. Item Therapeutics, Inc Bought 500 ITRM @$1.60. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Iterum Therapeutics NASDAQ Updated Mar 26, 2021 11:59 PM. These products are aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. As of 2021 February 10, Wednesday current price of ITRM stock is 2.300$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Iterum Therapeutics Plc has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. Cancel. The Average Price target for ITRM set by the institutional analysts is $1.53 where High Estimate is $2.10, Median $1.53 and Low $1.01. DOW 0.00%. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.16. Earnings results for Iterum Therapeutics (NASDAQ:ITRM) Iterum Therapeutics plc is expected* to report earnings on 03/12/2021 before market open. Get Iterum Therapeutics stock price history and adjusted historical data with charts, graphs, and statistical analysis. View Iterum Therapeutics PLC ITRM investment & stock information. Iterum Therapeutics PLC (ITRM) stock is trading at $2.03 as of 10:06 AM on Wednesday, Sep 30, a rise of $1.39, or 215.81% from the previous closing price of $0.64. Log In. All Rights Reserved. At the very opening of the session, the stock price was $1.41 and reached a high price of $1.46, prior to closing the session it reached the value of $1.41. On average, analysts forecast that ITRM's EPS will be $-0.23 for 2021, with the lowest EPS forecast at $-0.25, and the highest EPS forecast at $-0.21. Iterum Therapeutics plc (ITRM) was trading higher Tuesday morning as it joins the group of stocks gaining popularity thanks to Reddit and other social media networks. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Their average twelve-month price target is $3.25, predicting that the stock has a possible upside of 112.42%. Iterum Therapeutics … In the face of being in the red during last session for losing 0%, in the last five days ITRM remained trading in the green while hitting it’s week-highest on Friday, Mar 19 when the stock touched … The average price target for ITRM by Institutional Analysts is $ 1.53, which is … 4 Wall Street analysts have issued ratings and price targets for Iterum Therapeutics in the last 12 months. The price target was set to $2.50 . All rights reserved. What's Happening With Iterum Therapeutics PLC Stock Today? Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. Please note that any opinions, estimates or forecasts regarding Iterum Therapeutics plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Iterum Therapeutics plc or its management. So far 44,876,255 shares have traded compared to average volume of 207,235 shares. Get Iterum Therapeutics stock price history and adjusted historical data with charts, graphs, and statistical analysis. This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. Iterum Therapeutics Earnings Estimates and Actuals by Quarter Disclaimer. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. No recent news for Iterum Therapeutics PLC. Real-time trade and investing ideas on Iterum Therapeutics ITRM from the largest community of traders and investors. Factset: FactSet Research Systems Inc.2019. © 2020 Cable News Network. The 2021 estimates are for Iterum Therapeutics plc earnings to increase by 69.5%, but the outlook for the next 5-year period is at 0% per year. Target @$10.00 date May 2,2022 Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens. Most Recent Rating. The report will be for the fiscal Quarter ending Dec 2020. The ITRM stock price is -276.25% off its 52-week high price of $6.02 and 71.81% above the 52-week low of … The company’s stock has been forecasted to trade at an average price of $1.5 over the course of the next 52 weeks, with a low of $1 and a high of $2. Iterum Therapeutics (ITRM) stock is taking off on Tuesday with heavy trading even without any news coming from the company. Iterum Therapeutics plc (ITRM) estimates and forecasts. Nov. 17, 2020 at 6:27 a.m. Earnings growth for 2021 is a modest +69.5%. View the latest ratings for ITRM. Analysts covering Iterum Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -2.437 for the next financial year. 1 year Iterum Therapeutics Forecast: 0 USD * About the Iterum Therapeutics Plc stock forecast As of 2021 February 10, Wednesday current price of ITRM stock is 2.300$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception). Insiders haven't bought Iterum Therapeutics stock in the last three months, but there was some selling. The average equity rating for ITRM stock is currently 3.20, trading closer to a bullish pattern in the stock market. Iterum Therapeutics Stock Looks Like a High-Risk Name Here Broad antibiotic market troubles should worry you about ITRM stock By Larry Ramer , … Iterum Therapeutics currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. Click here now. The average price target represents a 84.66% upside from the last price of $1.76. Iterum Therapeutics plc (ITRM) estimates and forecasts. S&P 500 0.00%. Post-Market 0.03 (2.13%) Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. NASDAQ 0.00%. Find real-time ITRM - Iterum Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business. What is ITRM's forecast return on equity (ROE) for 2021-2024? The price target was set to $2.50. Next Steps. Sign Up. Get Our PREMIUM Forecast … ITRM Stock Predictions, Articles, and Iterum Therapeutics Plc News. Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). It is understandable that investor optimism is growing ahead of the company’s current quarter results. Get the hottest stocks to trade every day before the market opens 100% free. Get the hottest stocks to trade every day before the market opens 100% free. The company’s stock price has collected -15.57% of loss in the last five trading sessions. Get the latest Iterum Therapeutics (ITRM) stock price quote with real-time news, financials, charts and other important investing information. Our Company So far 44,876,255 shares have traded compared to average volume of 207,235 shares. Iterum Therapeutics plc (NASDAQ:ITRM) trade information. Rooms Shows Rankings Earnings Calendar Shop. Iterum Therapeutics Plc (ITRM) Stock Price has been Trending Strongly with an ADX reading of 38.29 as per the Weekly Chart. Iterum Therapeutics stock forecast & analyst price target predictions based on 2 analysts offering 12-months price targets for ITRM in the last 3 months. Get the hottest stocks to trade every day before the market opens 100% free. All rights reserved. Find the latest Iterum Therapeutics plc (ITRM) stock quote, history, news and other vital information to help you with your stock trading and investing. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.16. Iterum Therapeutics is United States Stock traded on NASDAQ Exchange Iterum Therapeutics Plc Stock Forecast, "ITRM" Stock Predictons by days: 2021. Ra Capital Management reportedly disclosed ownership of 13,730,376 shares of Iterum Therapeutics plc by filing a 13G form with the Securities and Exchange Commission. In that case, then, we find that the current price level is +56.25% off the targeted high while a plunge would see the stock lose 25% from current levels. The stock's lowest day price was 1.34. The projected low price target is $2 while the price target rests at a high of $2.5. The company, currently valued at $282.37 Million, closed the last trade at $1.6 per share which meant it lost -$0.07 on the day or -4.19% during that session. A "buy" rating indicates that analysts believe ITRM will outperform the market and that investors should add to their positions of Iterum Therapeutics. This is a -7.19 percent down since the beginning of the trading day. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy." Iterum Therapeutics Plc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 32 means that 68% of stocks appear more favorable to our system. ITRM's Return on Equity is forecast to be low in 3 years (8.94%); analysts are not confident in the firm's ability to efficiently generate return on equity, ITRM is forecast to generate lower Return on Assets (-13.78%) than the US Biotechnology industry average (21.58%). And there weren't any purchases to give us comfort, over the last year. HC Wainwright is very positive to ITRM and gave it a "Neutral - Buy" rating on March 22, 2021. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Iterum Therapeutics against related stocks people … Iterum Therapeutics plc Ordinary Share (ITRM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Capital Management Lp Ra's Iterum Therapeutics shares are currently valued at $19.46M. Iterum Therapeutics stock has been on a bull run in the past few days - shares have risen in value from $1.3 on February 4th, to $2.73 at the time of writing - a gain of 110%. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Iterum Therapeutics stock price target cut to $2 from $4 at SVB Leerink. (NASDAQ: ITRM) Iterum Therapeutics's current Earnings Per Share (EPS) is -$2.17. The stock's lowest day price was 1.34. Iterum Therapeutics PLC (ITRM) stock is trading at $2.03 as of 10:06 AM on Wednesday, Sep 30, a rise of $1.39, or 215.81% from the previous closing price of $0.64. Get the latest Iterum Therapeutics PLC ITRM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Get Our PREMIUM Forecast Now, from ONLY $6.69! Iterum Therapeutics plc (NASDAQ: ITRM) is 109.30% higher on its value in year-to-date trading and has touched a low of $0.45 and a high of $6.02 in the current 52-week trading range. What is ITRM's revenue growth forecast for 2021-2023? Earnings results for Iterum Therapeutics (NASDAQ:ITRM) Iterum Therapeutics plc is expected* to report earnings on 03/12/2021 before market open. Iterum Therapeutics is selling for 1.42 as of the 25th of March 2021. Find the latest Iterum Therapeutics plc (ITRM) stock quote, history, news and other vital information to help you with your stock trading and investing. Iterum Therapeutics plc (NASDAQ:ITRM) shares, dropped in value on Friday, Mar 19, with the stock price down by 0% to the previous day’s close as weak demand from buyers trailed the stock to $1.65. Home. Get the latest Iterum Therapeutics PLC ITRM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Iterum Therapeutics is selling for 1.41 as of the 27th of March 2021. Volume today is more active than usual. Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global … Click here now. Furthermore, Iterum Therapeutics plc (ITRM)’s beta value is 0, and its average true range (ATR) is 0.33. Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens. Iterum Therapeutics plc, which has a market valuation of $188.17 Million, is expected to release its quarterly earnings report on March 12, 2021. Iterum Therapeutics plc (ITRM) is priced at $1.36 after the most recent trading session. In 2023, ITRM is forecast to generate $-9,898,106 in earnings, with the lowest earnings forecast at $-12,910,574 and the highest earnings forecast at $-6,885,639. The average price target is $3.25, with a high forecast of $7.00 and a low forecast of $1.50. Please note that any opinions, estimates or forecasts regarding Iterum Therapeutics plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Iterum Therapeutics plc or its management. The one-year ITRM stock forecast points to a potential downside of -18.0. The company’s stock has been forecasted to trade at an average price of $1.5 over the course of the next 52 weeks, with a low of $1 and a high of $2. The trade occurred on Jun 02 and was made at $1.61 per share for $0.64 million. What is ITRM's Earnings Per Share (EPS) forecast for 2021-2023? See Iterum Therapeutics plc (ITRM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. In 2023, ITRM is forecast to generate $714,987,560 in revenue, with the lowest revenue forecast at $215,176,225 and the highest revenue forecast at $1,214,841,931. Real-time trade and investing ideas on Iterum Therapeutics ITRM from the largest community of traders and investors. Iterum Therapeutics plc is expected to release its quarterly report on 05/19/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19.The EPS is expected to shrink by -32.40% this year. Get the latest Iterum Therapeutics (ITRM) stock price quote with real-time news, financials, charts and other important investing information. If you are looking for stocks with good return, Iterum Therapeutics Plc stock can be a bad, high-risk 1-year investment option. Iterum Therapeutics (NASDAQ: ITRM) is owned by 16.23% institutional shareholders, 55.98% Iterum Therapeutics insiders, and 27.79% retail investors. Jan. 24, 2020 at 7:41 a.m. Iterum Therapeutics Plc real time quote is equal to 1.655 USD at 2021-03-19, but your current investment may be devalued in the future. Iterum Therapeutics (NASDAQ: ITRM) is owned by 16.23% institutional shareholders, 55.98% Iterum Therapeutics insiders, and 27.79% retail investors.